L'hôpital Saint-Joseph est un hôpital généraliste privé situé dans le 14ᵉ arrondissement de Paris. Il appartient à la Fondation Hôpital Saint-Joseph qui gère plusieurs établissements privés sans but lucratif.

During the past decade, Groupe Hospitalier Paris Saint-Joseph conducted 361 clinical trials. In the 10-year time frame, 361 clinical trials started and 14 clinical trials were completed, i.e. on average, 3.9% percent of trials that started reached the finish line to date. In the past 5 years, 198 clinical trials started and 7 clinical trials were completed. i.e. 3.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Groupe Hospitalier Paris Saint-Joseph" #1 sponsor was "Groupe Hospitalier Paris Saint Joseph" with 260 trials, followed by "Intergroupe Francophone de Cancerologie Thoracique" with 13 trials sponsored, "Assistance Publique - Hôpitaux de Paris" with 11 trials sponsored, "UNICANCER" with 10 trials sponsored and "Hopital Foch" with 10 trials sponsored. Other sponsors include 122 different institutions and companies that sponsored additional 95 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Groupe Hospitalier Paris Saint-Joseph" #1 collaborator was "Ministry of Health, France" with 7 trials as a collaborator, "Institut Pasteur" with 4 trials as a collaborator, "Assistance Publique - Hôpitaux de Paris" with 3 trials as a collaborator, "AstraZeneca" with 3 trials as a collaborator and "Centre Hospitalier Victor Dupouy" with 3 trials as a collaborator. Other collaborators include 122 different institutions and companies that were collaborators in the rest 119 trials.

According to Clinical.Site data, the most researched conditions in "Groupe Hospitalier Paris Saint-Joseph" are "Stroke" (14 trials), "Covid19" (12 trials), "Acetabular Fracture" (7 trials), "Breast Cancer" (7 trials) and "COVID-19" (7 trials). Many other conditions were trialed in "Groupe Hospitalier Paris Saint-Joseph" in a lesser frequency.

Most popular intervention types in "Groupe Hospitalier Paris Saint-Joseph" are "Other" (104 trials), "Drug" (77 trials), "Device" (52 trials), "Procedure" (31 trials) and "Diagnostic Test" (21 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (17 trials), "No intervention" (13 trials), "Gemcitabine" (7 trials), "radiation therapy" (4 trials) and "Atezolizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Groupe Hospitalier Paris Saint-Joseph" are 380 trials for "All" genders, 38 trials for "Female" genders and 10 trials for "Male" genders.

Currently, there are NaN active trials in "Groupe Hospitalier Paris Saint-Joseph". 11 are not yet recruiting, 71 are recruiting, 109 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 204 completed trials in Groupe Hospitalier Paris Saint-Joseph, 1 suspended trials, and 18 terminated clinical trials to date.

Out of the total trials that were conducted in Groupe Hospitalier Paris Saint-Joseph, 4 "Phase 1" clinical trials were conducted, 25 "Phase 2" clinical trials and 51 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 10 trials, and there were also 116 trials that are defined as “Not Applicable".

Groupe Hospitalier Paris Saint-Joseph has several departments that took part in Clinical trials: "GH Paris Saint Joseph; Hopital De Jour Oncologie" - 6 trials, "Groupe Hopitalier Paris Saint Joseph Service de neurologie" - 2 trials, "GH Paris Saint Joseph; Pneumologie" - 2 trials